The anticoagulants market would grow at a CAGR of 9.09% over the predicted time frame. The market is expected to increase in value from US$ 34.91 Bn in 2022 to US$ 70 Bn in 2030.
Key Takeaway:
- By indicated disease, the pulmonary embolism segment has contributed 75% market share in 2021.
- By drug category, the factor Xa inhibitor segment accounted 56% market share in 2021.
- By distribution channel, the hospital pharmacy segment has made up 50% market share in 2021.
- North America region accounted 58% market share in 2021.
The on anticoagulants
Market, which provides a business strategy, research & development
activities, concise outline of the market valuation, valuable insights
pertaining to market share, size, supply chain analysis, competitive landscape
and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1796
Report Scope of the Anticoagulants Market
| Report Coverage | Details |
| Market Size by 2030 | USD 70 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 9.09% |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Indication of Disease, Administration Route, Drug Class, Distribution Channel, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Anticoagulants Market. The report provides a
comprehensive analysis of key factors that are expected to drive the growth of
this market. This study also provides a detailed overview of the opportunities
along with the current trends observed in the Anticoagulants market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Anticoagulants market are
included as given below:
Anticoagulants Market Key Players
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Bayer AG
- Boehringer Ingelheim GmbH
- Aspen Holdings
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanofi S.A.
- Portola Pharmaceuticals
Market Segments
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Atrial Fibrillation
- Heart Attacks
- Others
By Administration Route
- Oral
- Injectable
By Drug Class
- NOACs
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa & lixiana
- Pradaxa
- Heparin & LMWH
- Vitamin K Antagonist
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacy
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global anticoagulants
market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the anticoagulants
market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anticoagulants Market
5.1. COVID-19 Landscape: Anticoagulants Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anticoagulants Market, By Indication of disease
8.1. Anticoagulants Market, by Indication of disease, 2022-2030
8.1.1. Pulmonary Embolism (PE)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Deep Vein Thrombosis (DVT)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Atrial Fibrillation
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Heart Attacks
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anticoagulants Market, By Administration Route
9.1. Anticoagulants Market, by Administration Route e, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anticoagulants Market, By Drug Class
10.1. Anticoagulants Market, by Drug Class, 2022-2030
10.1.1. NOACs
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Heparin & LMWH
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Vitamin K Antagonist
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anticoagulants Market, By Distribution Channel
11.1. Anticoagulants Market, by Distribution Channel, 2022-2030
11.1.1. Hospitals Pharmacies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anticoagulants Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Daiichi Sankyo Company
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BoehringerIngelheim GmbH
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aspen Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline Plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Portola Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments